Background: Brain metastases are the most life-threatening among the secondary localizations of melanoma for their unresponsiveness to the surgical, radiotherapeutic and/or chemotherapeutic treatments. Methods: Accidentally, we observed a complete response (CR) in a patient undergoing chemotherapy with bleomycin, vincristine or Oncovin, CCNU or lomustine, dacarbazine (BOLD) regimen for metastatic melanoma including brain metastases, who was also treated with G-CSF to manage a concomitant leukopenia. After this observation, seven more patients with stage IV melanoma with brain metastases were treated with BOLD regimen repeated every 6 weeks with administration of G-CSF in the intervals. Results: Three patients presented CR (37.5%). Two patients stopped the treatment after two courses for evident progressive disease (25%). The other three patients showed stable disease (SD: 37.5%). Median duration of SD was 24 weeks. Among the eight patients, six (75%) achieved clinical benefit. Median time to progression was 8.5 months (range 0-74+ months). Median survival was 12.5 months (range 4-74+ months). Two patients are still alive and disease-free after 74 and 57 months, respectively. Conclusion: We believe that the brilliant CR, the long duration of the disease-free intervals and the long survival in at least three of eight patients should encourage further research on BOLD with G-CSF for the treatment of advanced melanoma.

Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF / U., Bottoni; P., Bonaccorsi; Devirgiliis, Valeria; Panasiti, Vincenzo; R. G., Borroni; G., Trasimeni; Clerico, Rita; S., Calvieri. - In: JAPANESE JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0368-2811. - 35:9(2005), pp. 507-513. [10.1093/jjco/hyi141]

Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF

DEVIRGILIIS, VALERIA;PANASITI, VINCENZO;CLERICO, Rita;
2005

Abstract

Background: Brain metastases are the most life-threatening among the secondary localizations of melanoma for their unresponsiveness to the surgical, radiotherapeutic and/or chemotherapeutic treatments. Methods: Accidentally, we observed a complete response (CR) in a patient undergoing chemotherapy with bleomycin, vincristine or Oncovin, CCNU or lomustine, dacarbazine (BOLD) regimen for metastatic melanoma including brain metastases, who was also treated with G-CSF to manage a concomitant leukopenia. After this observation, seven more patients with stage IV melanoma with brain metastases were treated with BOLD regimen repeated every 6 weeks with administration of G-CSF in the intervals. Results: Three patients presented CR (37.5%). Two patients stopped the treatment after two courses for evident progressive disease (25%). The other three patients showed stable disease (SD: 37.5%). Median duration of SD was 24 weeks. Among the eight patients, six (75%) achieved clinical benefit. Median time to progression was 8.5 months (range 0-74+ months). Median survival was 12.5 months (range 4-74+ months). Two patients are still alive and disease-free after 74 and 57 months, respectively. Conclusion: We believe that the brilliant CR, the long duration of the disease-free intervals and the long survival in at least three of eight patients should encourage further research on BOLD with G-CSF for the treatment of advanced melanoma.
bold; brain metastases; g-csf; melanoma; polychemotherapy
01 Pubblicazione su rivista::01a Articolo in rivista
Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF / U., Bottoni; P., Bonaccorsi; Devirgiliis, Valeria; Panasiti, Vincenzo; R. G., Borroni; G., Trasimeni; Clerico, Rita; S., Calvieri. - In: JAPANESE JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0368-2811. - 35:9(2005), pp. 507-513. [10.1093/jjco/hyi141]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/363836
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 13
social impact